Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amrita Krishnan

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2025
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple MyelomaAjai Chari, Susan Bal, Sikander Ailawadhi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2006
Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?Amrita Krishnan, Auayporn Nademanee, Henry Fung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphomaRavi Bhatia, Khristine Van Heijzen, Ann Palmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphomaHenry C Fung, Patrick Stiff, Jeff Schriber, et al.
American Journal of Hematology|September 3, 2015
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myelomaShaji K Kumar, Amrita Krishnan, Betsy LaPlant, et al.
Future Oncology (London, England)|July 26, 2023
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myelomaAjai Chari, Elham Askari, Jo Caers, et al.
Advances in Therapy|February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic AnalysesXu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.
American Journal of Hematology|April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps ConferenceAjai Chari, Caitlin Costello, Amrita Krishnan, et al.
Blood|June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAjai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
Journal of Immunological Sciences|March 30, 2023
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic ChangesAda Alice Dona, James F Sanchez, Joycelynne M Palmer, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2025
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple MyelomaAjai Chari, Susan Bal, Sikander Ailawadhi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2006
Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?Amrita Krishnan, Auayporn Nademanee, Henry Fung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphomaRavi Bhatia, Khristine Van Heijzen, Ann Palmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2007
Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphomaHenry C Fung, Patrick Stiff, Jeff Schriber, et al.
American Journal of Hematology|September 3, 2015
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myelomaShaji K Kumar, Amrita Krishnan, Betsy LaPlant, et al.
Future Oncology (London, England)|July 26, 2023
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myelomaAjai Chari, Elham Askari, Jo Caers, et al.
Advances in Therapy|February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic AnalysesXu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.
American Journal of Hematology|April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps ConferenceAjai Chari, Caitlin Costello, Amrita Krishnan, et al.
Blood|June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAjai Chari, Attaya Suvannasankha, Joseph W Fay, et al.
Journal of Immunological Sciences|March 30, 2023
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic ChangesAda Alice Dona, James F Sanchez, Joycelynne M Palmer, et al.
Pageof 12